Aktienanalyse zu Neurosense Therapeutics Ltd (NRSN)NRSNNeurosense Therapeutics Ltd

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Neurosense Therapeutics Ltd is currently not a good buy due to significant financial losses and a delayed Phase 3 study. The current price is $1.60, which is far below the analyst target of $3.50 from Roth Capital, indicating potential upside but also high risk. The company's RSI is at 38.737, suggesting it is nearing oversold territory, but the overall trend remains negative with a 5-day change of -19.60%.